NASDAQ : HBIO
Harvard Bioscience, Inc. — Key statistics
Healthcare · Medical Instruments & Supplies · United States
Last price 8.8 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 40.06M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 40.52M |
| Enterprise Value | 78.22M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 10, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 4.55M |
| Shares Outstanding | 4.55M |
| Shares Change (YoY) | +1.81% |
| Shares Change (QoQ) | +1.18% |
| Owned by Insiders (%) | 7.12% |
| Owned by Institutions (%) | 30.10% |
| Float | 3.68M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | 49.44 |
| PS Ratio | 0.46 |
| Forward PS | 0.44 |
| PB Ratio | 5.46 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 62.24 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 0.89 |
| EV / EBITDA | 10.61 |
| EV / EBIT | 39.68 |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.87 |
| Quick Ratio | 0.85 |
| Debt / Equity | 5.96 |
| Debt / EBITDA | 4.52 |
| Debt / FCF | n/a |
| Interest Coverage | 0.30 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -89.95% |
| Return on Assets (ROA) | 1.58% |
| Return on Invested Capital (ROIC) | 2.23% |
| Return on Capital Employed (ROCE) | 3.83% |
| Weighted Average Cost of Capital (WACC) | 12.06% |
| Revenue Per Employee | $259,021 |
| Profits Per Employee | -$30,714 |
| Employee Count | 339 |
| Asset Turnover | 1.12 |
| Inventory Turnover | 1.65 |
Taxes
| Measure | Value |
|---|
| Income Tax | -129,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.51 |
| 52-Week Price Change | +99.33% |
| 50-Day Moving Average | 8.12 |
| 200-Day Moving Average | 6.44 |
| Relative Strength Index (RSI) | 68.78 |
| Average Volume (20 Days) | 16,315 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 50,161 |
| Short Previous Month | 44,996 |
| Short % of Shares Out | 1.10% |
| Short % of Float | 1.36% |
| Short Ratio (days to cover) | 3.05 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 87.81M |
| Gross Profit | 51.07M |
| Operating Income | 1.97M |
| Pretax Income | -10.54M |
| Net Income | -10.41M |
| EBITDA | 7.37M |
| EBIT | 1.97M |
| Loss Per Share | -$2.35 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 6.50M |
| Total Debt | 44.21M |
| Net Cash | -37.70M |
| Net Cash Per Share | -$8.28 |
| Equity (Book Value) | 7.42M |
| Book Value Per Share | 1.63 |
| Working Capital | 21.67M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 651,000 |
| Capital Expenditures | -1.77M |
| Depreciation & Amortization | 5.40M |
| Net Borrowing | 4.65M |
| Free Cash Flow | -1.12M |
| FCF Per Share | -$0.25 |
Margins
| Measure | Value |
|---|
| Gross Margin | 58.16% |
| Operating Margin | 2.24% |
| Pretax Margin | -12.00% |
| Profit Margin | -11.86% |
| EBITDA Margin | 8.39% |
| EBIT Margin | 2.24% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.81% |
| Shareholder Yield | -1.81% |
| Earnings Yield | -26.39% |
| FCF Yield | -2.76% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Mar 16, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -2.26 |
| Piotroski F-Score | 6 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |